Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HRS-7535 in obese adults with heart failure with mildly reduced or preserved ejection fraction
CTR20250391Phase 2Active
- Sponsor
- Shandong Sende
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-7535 in heart failure with preserved ejection fraction (HFpEF), heart failure with mid-range ejection fraction (HFmrEF), obesity, sponsored by Shandong Sende. Started Apr 2025; status: active.
02
Drugs
HRS-7535
03
Conditions
heart failure with preserved ejection fraction (HFpEF)heart failure with mid-range ejection fraction (HFmrEF)obesity
Beyond the preview
Go deeper on CTR20250391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250391.